| Identification | Back Directory | [Name]
1-Propanesulfonamide, N-[2-chloro-3-[(3,4-dihydro-3,5-dimethyl-4-oxo-6-quinazolinyl)amino]-4-fluorophenyl]-3-fluoro- | [CAS]
2573781-75-4 | [Synonyms]
Tinlorafenib
Tinlorafenib (compound 10)
1-Propanesulfonamide, N-[2-chloro-3-[(3,4-dihydro-3,5-dimethyl-4-oxo-6-quinazolinyl)amino]-4-fluorophenyl]-3-fluoro- | [Molecular Formula]
C19H19ClF2N4O3S | [MOL File]
2573781-75-4.mol | [Molecular Weight]
456.89 |
| Chemical Properties | Back Directory | [Boiling point ]
569.6±60.0 °C(Predicted) | [density ]
1.48±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 125 mg/mL (273.59 mM; Need ultrasonic) | [form ]
Solid | [pka]
7.20±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Tinlorafenib (PF-07284890) (compound 10) is an orally active BRAF kinase inhibitor, with IC50s of 4.25 and 2.7 nM for BRAFV600E/V600K respectively. Tinlorafenib demonstrates CNS penetration and can be used in the research of BRAF-associated malignant and benign tumors of the CNS as well as extracranial malignancies[1]. | [IC 50]
BRafV600E: 4.25 nM (IC50); BRafV600K: 2.7 nM (IC50) | [References]
[1] Barbour, et al. Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders. WO2020261156A1. |
|
|